This page shows the latest Barhemsys news and features for those working in and with pharma, biotech and healthcare.
Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... Edison previously predicted Barhemsys could add another $110m
FDA. The Cambridge, UK company has refiled the marketing application for Barhemsys (intravenous amisulpride) and says the US regulator will give it a rapid review with a proposed action date of ... Acacia was hit hard after the FDA issued complete
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...